Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13799418 | 0.75 | ALDH1A1 (0.42) | KCNJ1ALDH1A1PARP1KDM4ETDP1 | |
| SCHEMBL23565448 | 0.73 | OGA (0.68) | — | |
| SCHEMBL23314232 | 0.73 | OGA (0.68) | — | |
| SCHEMBL23314223 | 0.72 | OGA (0.62) | TDP1 | |
| SCHEMBL19300219 | 0.71 | KDM4E (0.62) | DRD2CYP2D6ALDH1A1SLC18A3KDM4E | |
| SCHEMBL24418002 | 0.71 | TDP1 (0.39) | KCNJ1ALDH1A1KDM4ETDP1 | |
| SCHEMBL25902209 | 0.70 | OGA (0.35) | KCNJ1DRD2DRD4CYP2D6ALDH1A1 | |
| SCHEMBL5547664 | 0.68 | BRD4 (0.55) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL21657656 | 0.66 | CREBBP (0.50) | ACHEALDH1A1KDM4ETDP1 | |
| SCHEMBL7916564 | 0.66 | CREBBP (0.50) | ACHEALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995090-B2 | Substituted dihydrobenzofuran glycosidase inhibitors | ASCENEURON SA (CH) | 2021-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995090-B2 | Substituted dihydrobenzofuran glycosidase inhibitors | GAA, ENGASE, BACE1 | KCNJ1 3422/4885DRD2 2697/4885DRD4 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.